All In Biotech

Drug Trial Radar · NCT07797335

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,778 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,778

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Jul 31, 2028

Study completion Sep 20, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Conditions

  • Type 2 Diabetes
  • Cardiovascular Risk

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm (administration to the same body part throughout the study).

  • Insulin glargine U-100Drug

    Insulin glargine U-100 will be administered subcutaneously using SoloSTAR pen-injector to one of the body parts: thigh, abdomen or upper arm (rotation of the injection site within body parts).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiority of zenagamtide versus insulin glargine: change in haemoglobin A1c (HbA1c)Time frame: From baseline (week 0) to week 52

Locations

330 sites in 16 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama · Not yet recruiting

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama · Recruiting

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama · Recruiting

  • Honor Health

    Scottsdale, Arizona · Not yet recruiting

  • First Valley Medical Group

    Lancaster, California · Recruiting

  • Headlands Research CTR Lincoln

    Lincoln, California · Recruiting

  • Torrance Clin Res Inst, Inc.

    Lomita, California · Recruiting

  • Pacific Clinical Studies

    Los Alamitos, California · Recruiting

  • VAGLAHS Clinical Research Center (CRC)

    Los Angeles, California · Not yet recruiting

  • Valley Clinical Trials, Inc.

    Northridge, California · Recruiting

  • Paradigm Clinical Research

    San Diego, California · Recruiting

  • N America Res Inst - San Dimas

    San Dimas, California · Recruiting

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California · Recruiting

  • Innovative Research of W FL

    Clearwater, Florida · Recruiting

  • Nature Coast Clin Rsrch_Crystal River

    Crystal River, Florida · Not yet recruiting

  • Florida Premier Cardiology

    Delray Beach, Florida · Not yet recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Recruiting

  • East Coast Institute For Research

    Jacksonville, Florida · Not yet recruiting

  • Jacksonville Ctr for Clin Res

    Jacksonville, Florida · Not yet recruiting

  • Clinical Research of Cent FL

    Lakeland, Florida · Recruiting

  • Life Spring Research Foundation LLC

    Miami, Florida · Recruiting

  • Optimus U, Corp

    Miami, Florida · Not yet recruiting

  • Flourish Research - North Miami

    Miami, Florida · Not yet recruiting

  • Inpatient Research Clinic LLC

    Miami Lakes, Florida · Not yet recruiting

  • San Marcus Res Clin Miami Lakes

    Miami Lakes, Florida · Recruiting

  • Trujillo Medical Centers

    Miramar, Florida · Recruiting

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida · Not yet recruiting

  • Ocala Cardiovascular Research

    Ocala, Florida · Recruiting

  • Suncoast Clinical Research, Inc.

    Palm Harbor, Florida · Not yet recruiting

  • Suncoast Research Associates LLC

    Pembroke Pines, Florida · Not yet recruiting

  • St Johns Center for Clin. Res

    Saint Augustine, Florida · Recruiting

  • Javara/Privia Med Grp GA,LLC

    Albany, Georgia · Recruiting

  • David Kavtaradze MD, Inc.

    Cordele, Georgia · Not yet recruiting

  • Atlanta Heart Specialist

    Tucker, Georgia · Not yet recruiting

  • Rocky Mountain Diab&Osteo Ctr

    Idaho Falls, Idaho · Recruiting

  • Elevate Clinical Research

    Gurnee, Illinois · Recruiting

  • Chicago Medical Research LLC

    Hazel Crest, Illinois · Recruiting

  • Genesis Orthopedics & Sports Medicine

    Oak Brook, Illinois · Not yet recruiting

  • Methodist Medical Center of Illinois

    Peoria, Illinois · Not yet recruiting

  • American Health Network of IN LLC_Franklin

    Franklin, Indiana · Not yet recruiting

Showing 40 of 330 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.